Neuphoria Therapeutics Inc. (NEUP)
Neuphoria Therapeutics Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Millis, MA, US. The stock last traded at $2.35, up 1.29% on the session, giving a market capitalisation of $12.7M. On trailing twelve-month figures it carries a trailing P/E of -2.75, a net margin of -423.3%. Its beta of 0.77 implies it has historically moved less than the broad market.
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also develops Merck alpha7 positive allosteric modulators. It has a research collaboration and license agreement with Merck & Co., Inc. to develop alpha7 receptor positive allosteric modulators targeting cognitive dysfunction associated with Alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name to Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Millis, Massachusetts.
Neuphoria Therapeutics Inc. is most often compared with the following Healthcare names: